Oklahoma Patent of the Month – January 2023

Traditional image processing systems have advanced the medical industry and our understanding of a patient’s status. Some solutions can even readily segment certain anatomy, like bones, for in-depth review. Unfortunately, there has not been a solution for autonomously segmenting coronary artery vessel x-ray images. 

Kardiolytics Inc, a leader in medical imaging technology, has developed a novel solution for the efficient and autonomous segmentation of contrast-filled coronary artery vessels. The method uses advanced machine learning technologies such as a convolutional neural network (CNN) to process x-ray images, enabling a detailed segmentation of anatomy fragments in a matter of seconds.

The process begins with receiving an x-ray angiography scan of the coronary vessels, which is then preprocessed to output a preprocessed scan. The preprocessing step includes procedures such as windowing, filtering, and normalization, and may even include computing a Jerman filter response, which is then provided as input to a second channel of the segmentation convolutional neural network.

The trained CNN then performs autonomous coronary vessel segmentation and outputs a mask that denotes the coronary vessels. The result is a highly efficient and accurate representation of the coronary vessels, facilitating the diagnosis, treatment, and monitoring of coronary artery diseases.

Prior to Kardiolytics, physicians were reliant on complex, expensive, and highly invasive procedures that involve inserting probes into the heart to obtain the same diagnostic information that can now be readily derived from non-invasive imaging and AI processing. Kardiolytics’ solution is a significant advancement in medical imaging technology, offering a faster and more reliable way to detect and segment contrast-filled coronary artery vessels in x-ray images. With this new technology, medical professionals can diagnose and treat coronary artery diseases with greater ease and accuracy, ultimately improving patient outcomes.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts